May 1 (Reuters) - Eli Lilly and Co LLY.N:
ELI LILLY EXEC SAYS ANNOUNCED TARIFFS CURRENTLY IN EFFECT DO NOT MATERIALLY CHANGE CO'S 2025 FINANCIAL OUTLOOK - CONF CALL
LILLY EXEC SAYS EXPANSION OF TARIFFS IN OTHER GEOGRAPHIES OR INCREASES IN RETALIATORY TARIFFS WOULD HAVE A NEGATIVE EFFECT ON CO, INDUSTRY
LILLY EXEC SAYS RECENTLY INITIATED LIMITED MOUNJARO LAUNCH IN CHINA, EXPECT TO TO GRADUALLY INCREASE LAUNCH IN H2 AS SUPPLY BECOMES AVAILABLE
LILLY EXEC SAYS EXPECT US REGULATORY ACTION FOR MODIFIED DOSING REGIME FOR ALZHEIMER'S DRUG KISUNLA IN THE NEXT FEW MONTHS
LILLY EXEC SAYS PLANS TO START A NEW LATE-STAGE TRIAL FOR ITS DRUG RETATRUTIDE IN PATIENTS WITH OBESITY AND CHRONIC LOW BACK PAIN
LILLY EXEC SAYS CO HAS WITHDRAWN US APPLICATION FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION INDICATION FOR TIRZEPATIDE
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。